

I hereby certify that this correspondence is being transmitted by facsimile to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on May 7,
2002

QUINE INTELLECTUAL PROPERTY LAW GROUP

By: 
Evelyn Gomez

Attorney No: 12E-989110US

Client Ref: G67

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jagdish Parasrampur et al.

Application No.: 09/526,802

Filed: March 16, 2000

For: DHEA COMPOSITION AND
METHOD

Examiner: Sahiba N. Qazi

Art Unit: 1616

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231
Fax 703-305-4556

Dear Sir:

In response to the Office Action dated February 12, 2002, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks. The following documents are enclosed herewith:

- 1) Transmittal;
- 2) Marked copy of the amended claims; and
- 3) Courtesy copy of the pending claims.

AMENDMENT

In the Claims:

Please cancel claims 11-35.

Please add the following new claims:

36. (New) A pharmaceutical formulation comprising dehydroepiandrosterone (DHEA), at least 85% of which is present as the form I polymorph as determinable by solid state ¹³C NMR spectroscopy, and at least one pharmaceutical excipient.

37. (New) A pharmaceutical formulation comprising dehydroepiandrosterone (DHEA), greater than 95% of which is present as the form I polymorph as determinable by solid state ¹³C NMR spectroscopy, and at least one pharmaceutical excipient.